Skip to Content

Mebendazole

Medically reviewed by Drugs.com. Last updated on Jun 17, 2019.

Pronunciation

(me BEN da zole)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet Chewable, Oral:

Emverm: 100 mg [contains corn starch, fd&c yellow #6 (sunset yellow), saccharin sodium]

Brand Names: U.S.

  • Emverm

Pharmacologic Category

  • Anthelmintic

Pharmacology

Inhibits the formation of helminth microtubules; selectively and irreversibly blocks glucose uptake and other nutrients in susceptible adult intestine-dwelling helminths

Absorption

Oral: Poor; 5% to 10%; increased with food (Dayan 2003)

Distribution

Vd: 1 to 2 L/kg

Metabolism

Extensively hepatic

Excretion

Primarily feces (as unchanged drug and primary metabolite); urine (<2%)

Half-Life Elimination

3 to 6 hours

Protein Binding

90% to 95%

Special Populations: Hepatic Function Impairment

Plasma levels may be increased.

Use: Labeled Indications

Intestinal nematode infection: Treatment of patients ≥2 years of age with GI infections caused by Ancylostoma duodenale or Necator americanus (hookworms), Ascaris lumbricoides (roundworms), Enterobius vermicularis (pinworms), and Trichuris trichiura (whipworms).

Off Label Uses

Capillariasis

Data from case reports suggest that mebendazole may be beneficial for the treatment of capillariasis [Chunlertrith 1992]. Clinical experience also suggests the utility of mebendazole in the treatment of capillariasis [CDC 2012].

Echinococcosis, cystic (Echinococcus granulosus)

Data from a case series suggest that mebendazole may be beneficial in the treatment of cystic echinococcosis [Franchi 1999]. Clinical experience also suggests the utility of mebendazole in the treatment of cystic echinococcosis [CDC 2014].

Toxocariasis

Data from a small, randomized trial and an observational study support the use of mebendazole in the treatment of toxocariasis [Magnaval 1995], [Wisniewska-Ligier 2012]. Clinical experience also suggests the utility of mebendazole in the treatment of toxocariasis [CDC 2013a].

Trichinellosis (Trichinella spiralis)

Data from a limited number of patients studied suggest that mebendazole may be beneficial in the treatment of trichinellosis [Horstmann 1982]. Clinical experience also suggests the utility of mebendazole in the treatment of trichinellosis [CDC 2018c].

Trichostrongyliasis

Data from a randomized trial support the use of mebendazole in the treatment of trichostrongyliasis [Farahmandian 1977].

Contraindications

Hypersensitivity to mebendazole or any component of the formulation

Dosing: Adult

Ancylostoma duodenale or Necator americanus (hookworm): Oral: 100 mg twice daily for 3 days (manufacturer's labeling; CDC 2018b) or 500 mg as a single dose (CDC 2018b). Repeat in 3 weeks if not cured with initial treatment.

Ascariasis (roundworm): Oral: 100 mg twice daily for 3 days (manufacturer's labeling; CDC 2018a) or 500 mg as a single dose (CDC 2018a). Repeat in 3 weeks if not cured with initial treatment.

Capillariasis (off-label use): Oral: 200 mg twice daily for 20 days (CDC 2012).

Echinococcus, cystic (alternative agent) (off-label use): Oral: 40 to 50 mg/kg/day in 3 divided doses for 3 to 6 months (CDC 2014; Franchi 1999).

Enterobiasis (pinworm): Oral: 100 mg as a single dose (manufacturer's labeling); repeat in 2 weeks (CDC 2016a).

Toxocariasis (off-label use): Oral: 100 to 200 mg twice daily for 5 days (CDC 2013a).

Trichinellosis (Trichinella spiralis) (off-label use): Oral: 200 to 400 mg 3 times daily for 3 days, followed by 400 to 500 mg 3 times daily for 10 days (CDC 2018c).

Trichostrongyliasis (off-label use): Oral: 100 mg twice daily for 3 days (Farahmandian 1977).

Trichuriasis (whipworm): Oral: 100 mg twice daily for 3 days; repeat in 3 weeks if not cured with initial treatment.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Ancylostoma duodenale or Necator americanus (hookworm): Children and Adolescents (Limited data in children <2 years): Oral: 100 mg twice daily for 3 days or 500 mg once as a single dose; repeat in 3 weeks if not cured with initial treatment (CDC 2018b; Red Book [AAP 2018])

Ascariasis (roundworm): Children and Adolescents (Limited data in children < 2 years): Oral: 100 mg twice daily for 3 days or 500 mg once as a single dose; repeat in 3 weeks if not cured with initial treatment (CDC 2018a; Red Book [AAP 2018])

Capillariasis: Limited data available: Children and Adolescents: Oral: 200 mg twice daily for 20 to 30 days (CDC 2012; Red Book [AAP 2018])

Enterobiasis (pinworm): Children and Adolescents (Limited data in children <2 years): Oral: 100 mg as a single dose, repeat in 2 weeks. (Red Book [AAP 2018]).

Toxocariasis (roundworm, ocular larva migrans, visceral larva migrans): Limited data available: Children and Adolescents: Oral: 100 to 200 mg twice daily for 5 days (CDC 2013a; Red Book [AAP 2018])

Trichinellosis (trichinosis; Trichinella species): Limited data available: Children and Adolescents: Oral: 200 to 400 mg 3 times daily for 3 days, then 400 to 500 mg 3 times daily for 10 days (CDC 2018c; Red Book [AAP 2018])

Trichuriasis (whipworm): Children and Adolescents (Limited data in children <2 years): Oral: 100 mg twice daily for 3 days; repeat in 3 weeks if not cured with initial treatment (CDC 2013b; Red Book [AAP 2018]).

Administration

Oral: Administer with or without food. Tablets may be chewed, swallowed whole, or crushed and mixed with food.

Storage

Store at 20°C to 25°C (68°F to 77°F).

Drug Interactions

CarBAMazepine: May decrease the serum concentration of Mebendazole. Monitor therapy

Cimetidine: May increase the serum concentration of Mebendazole. Monitor therapy

Fosphenytoin: May decrease the serum concentration of Mebendazole. Monitor therapy

MetroNIDAZOLE (Systemic): Mebendazole may enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis may be increased. Avoid combination

Phenytoin: May decrease the serum concentration of Mebendazole. Monitor therapy

Adverse Reactions

Frequency not defined.

Gastrointestinal: Abdominal pain, anorexia, diarrhea, flatulence, nausea, vomiting

Hepatic: Hepatitis

<1%, postmarketing, and/or case reports: Abnormal hepatic function tests, agranulocytosis, alopecia, anaphylaxis, angioedema, decreased ejaculate volume (Parasitic Infections 2013), dizziness, glomerulonephritis, hepatitis, hypersensitivity reaction, leukopenia (Parasitic Infections 2013), neutropenia, seizure, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria

Warnings/Precautions

Concerns related to adverse effects:

• Bone marrow suppression: Neutropenia and agranulocytosis have been reported with high doses and prolonged use. Monitor CBC if used at higher doses or for a prolonged duration.

Disease-related concerns:

• Hepatic impairment: Use with caution; systemic exposure may be increased with hepatic impairment.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Pediatric: Experience with use in children <2 years of age is limited; convulsions have been reported postmarketing in pediatric patients <1 year.

Monitoring Parameters

Periodic hematologic, hepatic, and renal function; check for helminth ova in feces within 3-4 weeks following the initial therapy

Pregnancy Considerations

Untreated soil transmitted helminth infections during pregnancy are associated with adverse outcomes (eg, maternal iron deficiency anemia, low birth weight, neonatal and maternal death). Treatment of pinworm in pregnancy with mebendazole may be considered; however, the CDC suggests postponing therapy until the third trimester when possible (CDC 2016a).

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience abdominal pain, lack of appetite, flatulence, nausea, vomiting, or diarrhea. Have patient report immediately to prescriber seizures (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide